FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293116249> ?p ?o ?g. }

• W4293116249 abstract "Abstract Background The NMDA receptor (NMDAR) plays a key role in the central nervous system, e.g., for synaptic transmission. While synaptic NMDARs are thought to have protective characteristics, activation of extrasynaptic NMDARs might trigger excitotoxic processes linked to neuropsychiatric disorders. Since extrasynaptic NMDARs are typically GluN2B-enriched, the subunit is an interesting target for drug development and treatment monitoring. Recently, the novel GluN2B-specific PET radioligand (R) -[ 11 C]Me-NB1 was investigated in rodents and for the first time successfully translated to humans. To assess whether (R) -[ 11 C]Me-NB1 is a valuable radioligand for (repeated) clinical applications, we evaluated its safety, biodistribution and dosimetry. Methods Four healthy subjects (two females, two males) underwent one whole-body PET/MR measurement lasting for more than 120 min. The GluN2B-specific radioligand (R) -[ 11 C]Me-NB1 was administered simultaneously with the PET start. Subjects were measured in nine passes and six bed positions from head to mid-thigh. Regions of interest was anatomically defined for the brain, thyroid, lungs, heart wall, spleen, stomach contents, pancreas, liver, kidneys, bone marrow and urinary bladder contents, using both PET and MR images. Time-integrated activity coefficients were estimated to calculate organ equivalent dose coefficients and the effective dose coefficient. Additionally, standardized uptake values (SUV) were computed to visualize the biodistribution. Results Administration of the radioligand was safe without adverse events. The organs with the highest uptake were the urinary bladder, spleen and pancreas. Organ equivalent dose coefficients were higher in female in almost all organs, except for the urinary bladder of male. The effective dose coefficient was 6.0 µSv/MBq. Conclusion The GluN2B-specific radioligand (R) -[ 11 C]Me-NB1 was well-tolerated without reported side effects. Effective dose was estimated to 1.8 mSv when using 300 MBq of presented radioligand. The critical organ was the urinary bladder. Due to the low effective dose coefficient of this radioligand, longitudinal studies for drug development and treatment monitoring of neuropsychiatric disorders including neurodegenerative diseases are possible. Trial registration Registered on 11th of June 2019 at https://www.basg.gv.at (EudraCT: 2018-002933-39)." @default.
• W4293116249 created "2022-08-26" @default.
• W4293116249 creator A5000308568 @default.
• W4293116249 creator A5018021326 @default.
• W4293116249 creator A5023419818 @default.
• W4293116249 creator A5025247342 @default.
• W4293116249 creator A5031832723 @default.
• W4293116249 creator A5032669789 @default.
• W4293116249 creator A5043061870 @default.
• W4293116249 creator A5044226143 @default.
• W4293116249 creator A5046807922 @default.
• W4293116249 creator A5047331691 @default.
• W4293116249 creator A5048708393 @default.
• W4293116249 creator A5057349369 @default.
• W4293116249 creator A5060239102 @default.
• W4293116249 creator A5061241787 @default.
• W4293116249 creator A5065725115 @default.
• W4293116249 creator A5067862521 @default.
• W4293116249 creator A5073649949 @default.
• W4293116249 creator A5075113322 @default.
• W4293116249 creator A5077330365 @default.
• W4293116249 creator A5078486787 @default.
• W4293116249 creator A5091881379 @default.
• W4293116249 date "2022-08-26" @default.
• W4293116249 modified "2023-10-14" @default.
• W4293116249 title "Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1" @default.
• W4293116249 cites W1934517153 @default.
• W4293116249 cites W1966556202 @default.
• W4293116249 cites W2009856100 @default.
• W4293116249 cites W2024380057 @default.
• W4293116249 cites W2084161441 @default.
• W4293116249 cites W2088627102 @default.
• W4293116249 cites W2095159395 @default.
• W4293116249 cites W2095292761 @default.
• W4293116249 cites W2140899588 @default.
• W4293116249 cites W2148296362 @default.
• W4293116249 cites W2160593693 @default.
• W4293116249 cites W2208668986 @default.
• W4293116249 cites W2753013118 @default.
• W4293116249 cites W2913968632 @default.
• W4293116249 cites W2965802642 @default.
• W4293116249 cites W3112745571 @default.
• W4293116249 cites W3121165943 @default.
• W4293116249 cites W31644411 @default.
• W4293116249 cites W3204305905 @default.
• W4293116249 doi "https://doi.org/10.1186/s13550-022-00925-8" @default.
• W4293116249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36018389" @default.
• W4293116249 hasPublicationYear "2022" @default.
• W4293116249 type Work @default.
• W4293116249 citedByCount "1" @default.
• W4293116249 countsByYear W42931162492023 @default.
• W4293116249 crossrefType "journal-article" @default.
• W4293116249 hasAuthorship W4293116249A5000308568 @default.
• W4293116249 hasAuthorship W4293116249A5018021326 @default.
• W4293116249 hasAuthorship W4293116249A5023419818 @default.
• W4293116249 hasAuthorship W4293116249A5025247342 @default.
• W4293116249 hasAuthorship W4293116249A5031832723 @default.
• W4293116249 hasAuthorship W4293116249A5032669789 @default.
• W4293116249 hasAuthorship W4293116249A5043061870 @default.
• W4293116249 hasAuthorship W4293116249A5044226143 @default.
• W4293116249 hasAuthorship W4293116249A5046807922 @default.
• W4293116249 hasAuthorship W4293116249A5047331691 @default.
• W4293116249 hasAuthorship W4293116249A5048708393 @default.
• W4293116249 hasAuthorship W4293116249A5057349369 @default.
• W4293116249 hasAuthorship W4293116249A5060239102 @default.
• W4293116249 hasAuthorship W4293116249A5061241787 @default.
• W4293116249 hasAuthorship W4293116249A5065725115 @default.
• W4293116249 hasAuthorship W4293116249A5067862521 @default.
• W4293116249 hasAuthorship W4293116249A5073649949 @default.
• W4293116249 hasAuthorship W4293116249A5075113322 @default.
• W4293116249 hasAuthorship W4293116249A5077330365 @default.
• W4293116249 hasAuthorship W4293116249A5078486787 @default.
• W4293116249 hasAuthorship W4293116249A5091881379 @default.
• W4293116249 hasBestOaLocation W42931162491 @default.
• W4293116249 hasConcept C112705442 @default.
• W4293116249 hasConcept C126322002 @default.
• W4293116249 hasConcept C142724271 @default.
• W4293116249 hasConcept C149857219 @default.
• W4293116249 hasConcept C150903083 @default.
• W4293116249 hasConcept C170493617 @default.
• W4293116249 hasConcept C207001950 @default.
• W4293116249 hasConcept C2777807558 @default.
• W4293116249 hasConcept C2989005 @default.
• W4293116249 hasConcept C67018056 @default.
• W4293116249 hasConcept C67847695 @default.
• W4293116249 hasConcept C71924100 @default.
• W4293116249 hasConcept C75088862 @default.
• W4293116249 hasConcept C86803240 @default.
• W4293116249 hasConceptScore W4293116249C112705442 @default.
• W4293116249 hasConceptScore W4293116249C126322002 @default.
• W4293116249 hasConceptScore W4293116249C142724271 @default.
• W4293116249 hasConceptScore W4293116249C149857219 @default.
• W4293116249 hasConceptScore W4293116249C150903083 @default.
• W4293116249 hasConceptScore W4293116249C170493617 @default.
• W4293116249 hasConceptScore W4293116249C207001950 @default.
• W4293116249 hasConceptScore W4293116249C2777807558 @default.
• W4293116249 hasConceptScore W4293116249C2989005 @default.
• W4293116249 hasConceptScore W4293116249C67018056 @default.
• W4293116249 hasConceptScore W4293116249C67847695 @default.
• W4293116249 hasConceptScore W4293116249C71924100 @default.

• next